
This parenting hack will help your baby stop crying in five minutes, say experts
One issue that many parents struggle with is their babies' endless crying, especially when they are fed, changed and have no obvious reason to be upset. Now, scientists have looked into the most effective methods for soothing a squalling infant, and concluded that carrying a baby and walking with it for just five minutes can help them stop crying and lull them back to sleep. The study showed that this method was more effective than simply holding the baby, as pacing triggers physiological changes, such as slowing their heart rate.
Twenty-one infants were monitored in experiments led by Dr Kumi Kuroda. The tests tracked changes in heart rate and behaviour of the babies as their mothers carried out different activities with them, including carrying, pushing them in a pram and holding them while sitting.
It turned out that crying babies calmed down quicker and their heart rates slowed within 30 seconds when they were carried and walked around. A similar effect happened when the babies were in a rocking cot, but not when they were in a stationary crib or when the mother held them while sitting.
All of the infants were more calm after five minutes of holding and walking, while nearly half had fallen asleep. It's important to flag though, those who were put down to sleep after being comforted often woke up as soon as their bodies were no longer in contact with their mothers. If the babies were held as they slept for longer before being laid down, they were less likely to wake up.
Dr Kumi said: 'Even as a mother of four, I was very surprised to see the result. I thought baby waking during a lay-down was related to how they are put on the bed, such as their posture, or the gentleness of the movement. But our experiment did not support these general assumptions.'
Monitoring the babies' heartbeats, scientists noticed how even the smallest change in movement affected them. For example, their heart rates went up when their mothers turned around and when they stopped walking.
Dr Kumi recommends carrying a crying baby steadily for about five minutes until they stop, then sit with them while they sleep for eight minutes, and then place them in their beds.
The significant results of the study have even led to the development of an app that will alert parents if they need to pick up their baby. But we're sorry to say, this isn't a magical fix that will work every time on every single child either. However, it's certainly worth a try. The study focused on mothers with their babies, but Dr Kumi believes the response is likely to be the same with fathers and other guardians.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
5 hours ago
- Reuters
Novavax banks on vaccine supply partnerships to boost 2025 revenue
Aug 6 (Reuters) - Novavax (NVAX.O), opens new tab raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda (4502.T), opens new tab, sending its shares surging 15%. The biotech has been shifting its focus to commercializing vaccine candidates through partnerships. It relies on revenue from its licensing deal with French drugmaker Sanofi ( opens new tab and vaccines in development, including a COVID-flu combination shot and for bird flu that is currently undergoing lab testing. Novavax had licensed the rights for its COVID-19 shot, Nuvaxovid — also its sole commercial product — to Sanofi in an up to $1.2 billion deal last year. The company expects its 2025 adjusted revenue to be between $1 billion and $1.05 billion, up from $975 million to $1.03 billion forecast earlier. This excludes Sanofi sales and royalties. Novavax also beat Wall Street expectations for second-quarter revenue, driven by a $175 million milestone payment related to the U.S. approval of Nuvaxovid in May. It plans to start a post-marketing study on Nuvaxovid by the end of the year, and estimates that to cost between $70 million and $90 million. The company expects Sanofi to reimburse about 70% of the costs, while it will absorb the rest. Novavax's traditional protein-based COVID-19 shot offers an alternative technology to messenger RNA-based rivals from Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab, but has failed to make a mark in the U.S. vaccine market due to manufacturing issues and regulatory hurdles. The biotech, however, sees an opportunity after the U.S. Department of Health and Human Services said it would wind down mRNA vaccine development under its biomedical research unit, BARDA, which helps companies develop treatments and diagnostic tools to address public health threats. "There is the potential opportunity for us, particularly since other platforms may be taken out of consideration," Novavax Executive Vice President Silvia Taylor said on a post-earnings call. Novavax said it is working with BARDA on potential funding for its H5N1 bird flu vaccine candidate. It reported total quarterly revenue of $239 million, beating analysts' estimate of $147.96 million, according to data compiled by LSEG. Net income was down 34.4% at $106.51 million.


The Independent
7 hours ago
- The Independent
This matcha maker is our wellbeing editor's favourite accessory of 2025 – and it's less than £100
If I have just one claim I'm proud of, it's that I liked matcha before it was cool. The fresh emerald tea has been a favourite drink of mine long before it blew up on TikTok. However, it's always been pretty time-consuming to make. I love the fact that I can now find matcha on the high street and that all my favourite coffee shops serve it. However, sometimes, when I want a quality matcha latte with maximum health benefits – like an energy boost without the jitters that coffee can produce – he best way to get one is to make it at home. There are so many quality matcha brands now that I'm spoilt for choice. My favourites use ceremonial-grade matcha from the Uji region of Japan and have a perfectly balanced flavour. Sometimes I'll mix things up with a flavoured matcha or a blend with added collagen, but for the most part, I stick to the traditional pure green elixir. It usually takes a while to slowly whisk the bright green powder into a paste and then add the perfect amount of liquid for a frothy lump-free drink. I used to use a traditional straw hand whisk or an electric frother if in a hurry, until I discovered my favourite accessory of 2025: the matcha latte magic whisk (£99, This kitchen-top accessory has totally changed the game when it comes to whipping up a matcha. It makes lump-free lattes in seconds. How I tested I used the magic whisk for two months and made daily matcha lattes using a range of different high-quality matcha powders, including my favourites from Reformed, JP's Originals and Dirtea. Having been a matcha drinker for some time, I was able to compare the drinks the machine made to the ones I've handcrafted at home using a whisk and electric frother. I also assessed the machine using the following checklist: Consistency: I used a range of different matchas, and occasionally a healthy cacao powder, to test the consistency with added plant milks and water. Flavour: Gentle heating and whisking are crucial for a balanced flavour when it comes to making matcha, so I judged the magic whisk on its ability to deliver this while still saving time on hand whisking. Temperature: You don't want a scalding hot or a lukewarm matcha, so the heat is an important factor. I noted the final temperature when using different ingredients and adding milk or water at different points in the whisking process. Ease of use: I also judged the magic whisk on how easy it was to put together and use –I like a straightforward kitchen gadget. Cleaning: I also awarded points for how easy the machine was to disassemble and clean. Price: I compared the price of the whisk to similar machines like the Hotel Chocolat velvetiser and my electric frothers to assess value for money. Design: Finally, I reviewed the look and feel of the machine, the finish and how good it looked on the kitchen counter. Why you can trust IndyBest reviews Emilie Lavinia is The Independent' s fitness and wellbeing editor. She specialises in wellness products – from yoga mats to the best sleep aids. She has been reporting on wellbeing and reviewing wellness products for more than a decade and knows what it takes to identify a quality product. Along with a cohort of trusted experts, she recommends what's worth investing in and what's better off left on the shelf for IndyBest. Where matcha is concerned, she's also our resident matcha expert. She's been drinking it long before it became mainstream, and knows the importance of a good ceremonial-grade powder, and has consulted experts on its benefits.


Reuters
8 hours ago
- Reuters
Novavax raises annual revenue forecast on vaccine supply partnerships
Aug 6 (Reuters) - Novavax (NVAX.O), opens new tab raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply partnerships, including with South Korea's SK Bioscience ( opens new tab and Japan's Takeda (4502.T), opens new tab. Shares of the biotech were up 4.3% in premarket trading, after it also beat Wall Street expectations for second-quarter revenue, driven by a $175 million milestone payment related to U.S. approval of its COVID-19 shot, Nuvaxovid, in May. Novavax, which is shifting its focus to commercializing vaccine candidates through partnerships, had licensed the rights for Nuvaxovid, its sole commercial product, to French drugmaker Sanofi ( opens new tab in an up to $1.2 billion deal. The company raised its 2025 adjusted revenue forecast to between $1 billion and $1.05 billion, from $975 million to $1.03 billion earlier. This excludes Sanofi sales and royalties. "This quarter we continued to progress our growth strategy," said CEO John Jacobs. "We look forward to continuing to build on this foundation into the second half of the year." Novavax's traditional protein-based COVID-19 shot offers an alternative technology to messenger RNA-based rivals from Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab, but has failed to make a mark in the U.S. vaccine market due to manufacturing issues and regulatory hurdles. The biotech said it plans to conduct the post-marketing study on Nuvaxovid requested by the U.S. Food and Drug Administration in 2025 and 2026, and estimates it to cost between $70 million and $90 million. The company expects Sanofi to reimburse about 70% of the costs, while it will absorb the rest. Novavax reported total revenue of $239 million during the quarter, compared with analysts' average estimate of $147.96 million, according to data compiled by LSEG. Net income for the three months ended June 30 came in at $106.51 million, compared with $162.38 million a year earlier.